Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
58 studies found for:    Open Studies | "Hemophilia A"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Hemophilia A"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A
Conditions: Hemophilia A;   Severe Hemophilia A
Intervention: Biological: rVIII‑SingleChain
2 Not yet recruiting Efficacy and Safety of ADVATE Standard Prophylaxis to Hemophilia A
Condition: Hemophilia A
Intervention: Drug: Recombinant Human Coagulation Factor VIII for injection
3 Not yet recruiting Evaluate Efficacy and Safety of ADVATE in the Standard Prophylaxis Treatment of Severe or Moderately Severe Hemophilia A
Condition: Hemophilia A
Intervention: Drug: ADVATE
4 Recruiting Inhibitor Development in Patients With Hemophilia A Undergoing Surgery
Condition: Hemophilia A
Intervention:
5 Recruiting Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A
Condition: Severe Hemophilia A
Intervention: Drug: Alphanate SD/HT
6 Recruiting Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients
Condition: Hemophilia A
Interventions: Biological: Moroctocog alfa ( AF-CC);   Procedure: Laboratory tests
7 Not yet recruiting Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A
Condition: Haemophilia A
Intervention: Biological: Optivate 500IU
8 Not yet recruiting An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A
Condition: Hemophilia A
Intervention: Biological: BIIB031 (rFVIIIFc)
9 Recruiting Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery
Condition: Hemophilia A
Intervention: Drug: Recombinant Protein-Free Factor VIII (rAHF-PFM)
10 Not yet recruiting Exploratory Pilot Study of Physical Activity Monitoring in Adult Patients With Haemophilia A by Means of Accelerometry
Condition: Hemophilia A, Congenital
Intervention:
11 Recruiting ADVATE Hemophilia A Outcome Database (AHEAD)
Condition: Hemophilia A
Intervention: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
12 Recruiting Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function
Condition: Hemophilia A
Intervention:
13 Recruiting Retrospective Study in Chinese Pediatric Hemophilia A Patients With rFⅧ Contained Regular Prophylaxis
Condition: Hemophilia A
Intervention: Biological: BAY14-2222_Kogenate-FS FVIII
14 Unknown  Socialization of Adult Men With Congenital Hemophilia A or B
Conditions: Hemophilia A;   Hemophilia B
Intervention:
15 Recruiting Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
16 Recruiting Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A
Condition: Hemophilia A
Intervention: Biological: GreenGene™ F
17 Recruiting Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A
Condition: Hemophilia A
Interventions: Biological: GreenGene™ F and an approved recombinant Factor VIII product;   Biological: GreenGene™ F
18 Recruiting To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
19 Recruiting Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures
Condition: Hemophilia A
Intervention: Biological: PEGylated Recombinant factor VIII (rFVIII)
20 Recruiting Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years